CTI BioPharma (CTIC) announced top-line data from Phase 3 clinical trial, PERSIST-2, evaluating its lead product candidate pacritinib against physician-specified best available therapy (BAT), including Novartis' (NVS) Jakavi (ruxolitinib), in patients with advanced myelofibrosis showed statistically valid results in one of two co-primary endpoints. The results were generated from 221 patients who reached the primary analysis time point of Week 24 at the time the clinical hold was imposed by the FDA. Preliminary results showed a statistically significant response rate as measured by minimum spleen volume reduction (SVR) of 35% compared to BAT, including Jakavi (p<0.01). The other primary endpoint, at least a 50% reduction in Total Symptom Score (TSS) was not met (p=0.0791).